Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017636 (glioblastoma)
 18,345 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Coronary collateral vessels reduce the damage of ischemic myocardium after coronary obstruction. Recently, vascular endothelial growth factor (VEGF) has been shown to increase vascular permeability and enhance the endothelial cell growth, leading to neoangiogenesis. VEGF has been reported to be upregulated in some neoplasms with endothelial proliferation, such as glioblastoma and vascularised adenocarcinoma. However, the expression and role of VEGF in human heart and those in its diseased condition have not been investigated. To elucidate its pathophysiological role, we studied the transcription and distribution of VEGF mRNA in normal human and myocardial infarcted hearts. Samples were obtained from 15 autopsy cases with and without ischemic heart disease. VEGF mRNA transcription was examined by using RT-PCR and Southern blot analysis. In all cases VEGF mRNA was detected in atrias, ventricles and valves. The amounts of each VEGF subtypes in cardiomyocytes were different from those in valves. By in situ hybridization method, VEGF mRNA was found in cytoplasm of normal cardiomyocyte but not in the vessels. However, in the cases of acute myocardial infarction, VEGF mRNA was detected in vascular smooth muscle cells of arterioles around the coagulation necrosis of the infarction as well as in mononuclear cells which infiltrated in the granulation tissues. In contrast, VEGF mRNA signals in cardiomyocyte around the necrosis were as much as those in the normal cardiomyocyte in non-diseased areas. By immunohistochemical studies, the mononuclear cells were supposed to be macrophages. This study suggests that VEGF could play an important role in neovascularization in acute myocardial infarction, and suggests that VEGF may have some favorable effect on infarcted myocardium.
 ...
PMID:[The expression and the role of vascular endothelial growth factor (VEGF) in human normal and myocardial infarcted heart]. 795 3

The objective of this Review is to describe the safety and efficacy of adipose stem/stromal cells (ASC) and stromal vascular fraction (SVF) in treating common diseases and the next steps in research that must occur prior to clinical use. Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients. Sixty-nine studies were performed in preclinical models of disease. ASCs improved symptoms, fistula healing, remission, and recurrence rates in severe cases of inflammatory bowel disease. In osteoarthritis, ASC and SVF improved symptom-related, functional, radiographic, and histological scores. ASC and SVF were also shown to improve clinical outcomes in ischemic stroke, multiple sclerosis, myocardial ischemia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, chronic liver failure, glioblastoma, acute kidney injury, and chronic skin wounds. These effects were primarily paracrine in nature and mediated through reduction of inflammation and promotion of tissue repair. In the majority of human studies, autologous ASC and SVF from liposuction procedures were used, minimizing the risk to recipients. Very few serious, treatment-related adverse events were reported. The main adverse event was postprocedural pain. SVF and ASC are promising therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. Further randomized controlled trials must be performed to elaborate potential safety and efficacy prior to clinical use. Stem Cells 2018;36:1311-1328.
 ...
PMID:Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies. 2976 73